Skip to content

Press Releases

Nov 22, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705 restricted stock units (RSUs) to fifty-four new colleagues under Esperion’s 2017 Inducement Equity
Nov 17, 2019
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia.
Nov 12, 2019
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
  –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –  –   Over 52- Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo –  – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate Lyase (ACL)
Nov 07, 2019
Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28 th Annual Healthcare Conference in Phoenix on Tuesday, November 12, 2019 3:50 PM EST Stifel Healthcare
Nov 06, 2019
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. “The Esperion Lipid Management Team continues to lay a strong and durable foundation
Nov 04, 2019
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17, 2019.
Oct 29, 2019
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic Acid Bempedoic acid is our lead, non-statin, orally available, once-daily, low-density
Oct 25, 2019
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23 rd . The Summit was comprised of a panel of physicians and
Sep 05, 2019
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial – – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion of patient
Aug 30, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 27, 2019, the Compensation Committee of Esperion’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted